• First Published: 19 September 2022

• First Published: 19 September 2022

• First Published: 19 September 2022

• Pages: 901-902
• First Published: 19 September 2022

• Pages: 903-905
• First Published: 02 April 2022

• Pages: 906-908
• First Published: 01 May 2022

• Pages: 909-910
• First Published: 13 April 2022

• Pages: 911-913
• First Published: 12 March 2022

• Pages: 914-916
• First Published: 27 March 2022

• Pages: 917-919
• First Published: 03 May 2022

IMMUNE-MEDIATED DISEASES, DILI, AND BILIARY TRACT DISEASE

no

Bile multi-omics analysis classifies lipid species and microbial peptides predictive of carcinoma of gallbladder

Nupur Sharma,  Manisha Yadav,  Gaurav Tripathi,  Babu Mathew,  Vasundhra Bindal,  Sanyam Falari,  Viniyendra Pamecha,  Jaswinder Singh Maras, 

• Pages: 920-935
• First Published: 31 March 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury

Nureen H. Mohamad Zaki,  Junya Shiota,  Ashley N. Calder,  Theresa M. Keeley,  Benjamin L. Allen,  Kazuhiko Nakao,  Linda C. Samuelson,  Nataliya Razumilava, 

• Pages: 936-950
• First Published: 07 April 2022

HH-regulated CXCL1 orchestrates the early inflammatory response and biliary proliferation after EHBD injury through complex cellular crosstalk.

• Abstract
• Full text
• PDF
• References

LIVER CANCER

no

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

Haichuan Wang,  Yi Zhou,  Hongwei Xu,  Xue Wang,  Yi Zhang,  Runze Shang,  Marie O'Farrell,  Stephanie Roessler,  Carsten Sticht,  Andreas Stahl,  Matthias Evert,  Diego F. Calvisi,  Yong Zeng,  Xin Chen, 

• Pages: 951-966
• First Published: 25 January 2022

• Abstract
• Full text
• PDF
• References

no

KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration

Haihong Wang,  Biying Zhang,  Ruiqi Li,  Jiayuan Chen,  Guojie Xu,  Ying Zhu,  Jiao Li,  Qing Liang,  Qingling Hua,  Lanqing Wang,  Lu Wen,  Min Jin,  Jun Fan,  Dejun Zhang,  Lei Zhao,  Dandan Yu,  Zhenyu Lin,  Jinghua Ren,  Tao Zhang, 

• Pages: 967-981
• First Published: 02 February 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study

Antonio D’Alessio,  Claudia Angela Maria Fulgenzi,  Naoshi Nishida,  Martin Schönlein,  Johann von Felden,  Kornelius Schulze,  Henning Wege,  Vincent E. Gaillard,  Anwaar Saeed,  Brooke Wietharn,  Hannah Hildebrand,  Linda Wu,  Celina Ang,  Thomas U. Marron,  Arndt Weinmann,  Peter R. Galle,  Dominik Bettinger,  Bertram Bengsch,  Arndt Vogel,  Lorenz Balcar,  Bernhard Scheiner,  Pei-Chang Lee,  Yi-Hsiang Huang,  Suneetha Amara,  Mahvish Muzaffar,  Abdul Rafeh Naqash,  Antonella Cammarota,  Nicola Personeni,  Tiziana Pressiani,  Rohini Sharma,  Matthias Pinter,  Alessio Cortellini,  Masatoshi Kudo,  Lorenza Rimassa,  David J. Pinato, 

• Pages: 1000-1012
• First Published: 21 March 2022

In this retrospective study on a real-life cohort of 216 patients treated with Atezolizumab plus Bevacizumab, the combination did not show any unexpected safety signals. Treatment-related adverse events were comparable across Child-Pugh (CP) classes. CP-B patients achieved similar response rates to CP-A patients, despite inferior survival outcomes.

• Abstract
• Full text
• PDF
• References

Open Access

oa

Single-cell profiling of human CD127⁺ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma

Yuanlin He,  Jiajing Luo,  Guannan Zhang,  Yu Jin,  Nanxi Wang,  Jinying Lu,  Changxian Li,  Xiaohuan Guo,  Na Qin,  Juncheng Dai,  Yun Chen, 

• Pages: 1013-1029
• First Published: 04 March 2022

• Abstract
• Full text
• PDF
• References

LIVER PATHOBIOLOGY

no

Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity

Yun-Zhong Nie,  Yun-Wen Zheng,  Hideki Taniguchi, 

• Pages: 1030-1045
• First Published: 04 March 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a mouse model of Wilson’s disease

Hongxia Cai,  Xing Cheng,  Xiao-Ping Wang, 

• Pages: 1046-1057
• First Published: 27 March 2022

ATP7B gene therapy of autologous reprogrammed hepatocytes relieved liver copper accumulation in WD mice.

• Abstract
• Full text
• PDF
• References

LIVER FAILURE/ CIRRHOSIS/PORTAL HYPERTENSION

no

IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis

Gyongyi Szabo,  Mack Mitchell,  Craig J. McClain,  Srinivasan Dasarathy,  Bruce Barton,  Arthur J. McCullough,  Laura E. Nagy,  Aimee Kroll-Desrosiers,  David Tornai,  Hyesung Alice Min,  Svetlana Radaeva,  M. E. Blair Holbein,  Lisa Casey,  Jennifer Cuthbert, 

• Pages: 1058-1068
• First Published: 27 March 2022

In a multicenter randomized clinical trial we targeted the key elements of alcoholic hepatitis including inflammation, cellular injury and gut leakiness and compared combination therapy to corticosteroids on 180-day survival. Subjects with a clinical diagnosis of severe alcohol-associated hepatitis AH (MELD>20, MDF>32) were randomized to receive methylprednisolone (PRED) or a combination of the IL-1 receptor antagonist, anakinra plus zinc plus pentoxifylline. Survival at 28 days was similar between the COMB (83.4%) and PRED groups (81.2%) (HR=0.91, p=0.85). Survival curves separated by 90 days (COMB: 69.8%; PRED: 58.0%; HR=0.69, p=0.28). Survival at 28 days was similar between the COMB (83.4%) and PRED groups (81.2%) (HR=0.91, p=0.85). There were no unexpected serious adverse events. These results suggest that a combination of anakinra, pentoxifylline plus zinc provides similar survival benefits compared to corticosteroid therapy in severe AH.

• Abstract
• Full text
• PDF
• References

no

Variability in serum creatinine is associated with waitlist and post–liver transplant mortality in patients with cirrhosis

Giuseppe Cullaro,  Chi-yuan Hsu,  Jennifer C. Lai, 

• Pages: 1069-1078
• First Published: 31 March 2022

• Abstract
• Full text
• PDF
• References

no

Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis

Jennifer A. Flemming,  Hala Muaddi,  Maja Djerboua,  Paula Neves,  Gonzalo Sapisochin,  Nazia Selzner, 

• Pages: 1079-1089
• First Published: 21 March 2022

The graphical abstracts shows association between social determinant of health and rates of liver transplantation in patients with liver cirrhosis.

• Abstract
• Full text
• PDF
• References

PEDIATRICS

STEATOHEPATITIS

no

FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase–Caspase 6 signal axis

Lintao Song,  Luyao Wang,  Yushu Hou,  Jie Zhou,  Chuchu Chen,  Xianxi Ye,  Wenliya Dong,  Huan Gao,  Yi Liu,  Guanting Qiao,  Tongtong Pan,  Qiong Chen,  Yu Cao,  Fengjiao Hu,  Zhiheng Rao,  Yajing Chen,  Yu Han,  Minghua Zheng,  Yongde Luo,  Xiaokun Li,  Yongping Chen,  Zhifeng Huang, 

• Pages: 1105-1120
• First Published: 12 February 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Ibon Martínez-Arranz,  Chiara Bruzzone,  Mazen Noureddin,  Ruben Gil-Redondo,  Itziar Mincholé,  Maider Bizkarguenaga,  Enara Arretxe,  Marta Iruarrizaga-Lejarreta,  David Fernández-Ramos,  Fernando Lopitz-Otsoa,  Rebeca Mayo,  Nieves Embade,  Elizabeth Newberry,  Bettina Mittendorf,  Laura Izquierdo-Sánchez,  Vaclav Smid,  Jorge Arnold,  Paula Iruzubieta,  Ylenia Pérez Castaño,  Marcin Krawczyk,  Urko M. Marigorta,  Martine C. Morrison,  Robert Kleemann,  Antonio Martín-Duce,  Liat Hayardeny,  Libor Vitek,  Radan Bruha,  Rocío Aller de la Fuente,  Javier Crespo,  Manuel Romero-Gomez,  Jesus M Banales,  Marco Arrese,  Kenneth Cusi,  Elisabetta Bugianesi,  Samuel Klein,  Shelly C. Lu,  Quentin M. Anstee,  Oscar Millet,  Nicholas O. Davidson,  Cristina Alonso,  José M. Mato, 

• Pages: 1121-1134
• First Published: 26 February 2022

• Abstract
• Full text
• PDF
• References

no

Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score

Rish K. Pai,  Vipul Jairath,  Malcolm Hogan,  Guangyong Zou,  Oyedele A. Adeyi,  Quentin M. Anstee,  Bashar A. Aqel,  Cynthia Behling,  Elizabeth J. Carey,  Andrew D. Clouston,  Kathleen Corey,  Brian G. Feagan,  David E. Kleiner,  Christopher Ma,  Stefanie C. McFarlane,  Mazen Noureddin,  Vlad Ratziu,  Mark A. Valasek,  Zobair M. Younossi,  Stephen A. Harrison,  Rohit Loomba, 

• Pages: 1150-1163
• First Published: 25 March 2022

• Abstract
• Full text
• PDF
• References

VIRAL HEPATITIS

no

Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization

Maika S. Deffieu,  Camille M. H Clément,  Cristina M. Dorobantu,  Emma Partiot,  Yonis Bare,  Orestis Faklaris,  Benjamin Rivière,  Nilda Vanesa Ayala-Nunez,  Thomas F. Baumert,  Philippe Rondé,  Yves Mély,  Vincent Lucansky,  Raphael Gaudin, 

• Pages: 1164-1179
• First Published: 07 April 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose

Michael G. Bruce,  Dana Bruden,  Debby Hurlburt,  Julie Morris,  Sara Bressler,  Gail Thompson,  Danielle Lecy,  Karen Rudolph,  Lisa Bulkow,  Thomas Hennessy,  Brenna C. Simons,  Mark K. Weng,  Noele Nelson,  Brian J. McMahon, 

• Pages: 1180-1189
• First Published: 23 March 2022

• Abstract
• Full text
• PDF
• References

Open Access

oa

A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice

Timothy Donnison,  Joey McGregor,  Senthil Chinnakannan,  Claire Hutchings,  Rob J. Center,  Pantelis Poumbourios,  Paul Klenerman,  Heidi E. Drummer,  Eleanor Barnes, 

• Pages: 1190-1202
• First Published: 21 March 2022

• Abstract
• Full text
• PDF
• References

• Pages: 1203-1218
• First Published: 28 June 2022

Criteria for downstaging.

• Pages: 1219-1230
• First Published: 17 February 2022

• Pages: E69-E70
• First Published: 05 April 2022

• Pages: E71-E72
• First Published: 21 April 2022

• Page: E73
• First Published: 13 April 2022

• Pages: E74-E75
• First Published: 28 April 2022

• Pages: E76-E77
• First Published: 28 April 2022

• Pages: E78-E79
• First Published: 03 May 2022

• Pages: E80-E81
• First Published: 03 May 2022

• Pages: E82-E83
• First Published: 03 May 2022

• Pages: E84-E85
• First Published: 23 May 2022

• Page: E86
• First Published: 23 May 2022

• Page: E87
• First Published: 10 June 2022

• Page: E88
• First Published: 10 June 2022

• Pages: E89-E90
• First Published: 11 June 2022

• Page: E91
• First Published: 11 June 2022

• Page: E92
• First Published: 13 June 2022

• Page: E93
• First Published: 13 June 2022

• First Published: 19 September 2022

• First Published: 19 September 2022